KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Safety and Immunogenicity of sIPV in Healthy Infants Aged 2 Months Following Sequential Immunization Program Combination with bOPV: A Phase 3, Randomized, Blinded, Parallel Positive-Controlled Clinical Trial. PMID 41295467 · Vaccines (Basel) · 2025-Oct-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Gabapentin versus placebo for the treatment of acute lumbosacral radicular pain caused by disc herniation: study protocol of the GRADE randomized controlled double-blind superiority trial. PMID 41137125 · Trials · 2025-Oct-24 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy of Fuzheng Quxie Formula Against Postoperative Metastasis of Lung Cancer in Stage IIA-IIIA With Negative Driver Genes: Protocol for a Multicenter, Double-Blind, Randomized Controlled Trial. PMID 41135941 · JMIR Res Protoc · 2025-Oct-24 This is a protocol for a randomized trial, not an original formal-result report. The abstract explicitly states it is a protocol (publication type 'Clinical Trial Protocol') and that results are not yet published. The phase is not confirmed as Phase III or II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine. PMID 41058426 · Vaccine · 2025-Oct-24 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. PMID 40911402 · Cardiovasc Res · 2025-Oct-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed Glioblastoma. PMID 39567017 · Magn Reson Med Sci · 2025-Oct-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer. PMID 41226343 · Int J Mol Sci · 2025-Oct-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of the safety and efficacy of moderately hypofractionated and conventionally fractionated radiotherapy for localized prostate cancer: evidence from 9074 men in 13 randomized clinical trials. PMID 41131510 · BMC Cancer · 2025-Oct-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. PMID 41126443 · Ann Surg · 2025-Oct-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. PMID 41025556 · N Engl J Med · 2025-Oct-23 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. PMID 40888725 · N Engl J Med · 2025-Oct-23 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Expanded Hemodialysis with the Theranova Dialyzer on the Platelet-to-Lymphocyte Ratio and Inflammatory Markers. PMID 41295836 · Toxins (Basel) · 2025-Oct-22 The study is a randomized controlled trial in hemodialysis patients, evaluating a dialyzer (a device), not a drug. The primary endpoints are inflammatory biomarkers (PLR, TNF-α), not time-to-event efficacy outcomes. It is not an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis. PMID 41125403 · RMD Open · 2025-Oct-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Changes in frailty based on minimally important difference and the impact of spironolactone on frailty in heart failure with preserved ejection fraction: insights from the TOPCAT trial. PMID 41125402 · Open Heart · 2025-Oct-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ultrasound-guided erector spinae plane block versus rhomboid intercostal sub-serratus plane block for postoperative analgesia in open radical nephrectomy: a randomized clinical study. PMID 41120933 · BMC Anesthesiol · 2025-Oct-22 The study is a randomized trial in an oncology surgical context (open radical nephrectomy for renal malignancy) but it is an analgesia study comparing two nerve block techniques (ESPB vs. RISS) using bupivacaine. It is not a trial of a systemic drug intervention for cancer treatment (e.g., chemotherapy, targeted therapy, immunotherapy). The primary endpoint is morphine consumption (an analgesic outcome), not a time-to-event oncology efficacy endpoint like OS or PFS. Therefore, it does not meet the criteria for inclusion in the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. PMID 41120118 · Eur Heart J · 2025-Oct-22 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading. PMID 40380787 · Nicotine Tob Res · 2025-Oct-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era. PMID 41171295 · Oncology (Williston Park) · 2025-Oct-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using Radiomics Features of Voxel-Wise DCE-MRI Time-Intensity-Curve Profile Maps. PMID 41153841 · Biomedicines · 2025-Oct-21 The study is a retrospective diagnostic/radiomics analysis to predict axillary lymph node metastasis in breast cancer. It is not a randomized trial, does not involve a drug intervention, and does not have a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study. PMID 41121202 · BMC Med · 2025-Oct-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM). PMID 41120904 · BMC Cancer · 2025-Oct-21 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome. PMID 41065238 · J Am Heart Assoc · 2025-Oct-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. PMID 41061701 · Cell Rep Med · 2025-Oct-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial. PMID 40960806 · JAMA · 2025-Oct-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. PMID 40906494 · JAMA · 2025-Oct-21 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis. PMID 41150456 · Vaccines (Basel) · 2025-Oct-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of vitamin D supplementation during pregnancy and lactation on the development of infants born to Tanzanian women living with HIV: a secondary analysis of a randomised controlled trial. PMID 41120170 · BMJ Open · 2025-Oct-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of Adaptive Blood Purification for Septic Shock (EABPSS): protocol for a randomised, multicentre, parallel controlled study. PMID 41120165 · BMJ Open · 2025-Oct-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pre-existing infiltration with T cells and CD14+ myeloid cells is associated with treatment response to imiquimod in primary and recurrent vulvar high-grade squamous intraepithelial lesions. PMID 41120128 · J Immunother Cancer · 2025-Oct-20 The record describes a biomarker-focused secondary analysis of a phase III randomized trial. While it meets criteria for oncology, human, randomized, phase III, and drug intervention, it lacks a time-to-event efficacy endpoint (like OS, PFS, DFS, or their associated Kaplan-Meier/HR analysis). The primary outcome is a categorical clinical response. Therefore, it is excluded.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Development and preliminary testing of a culturally competent behaviour change intervention framework to enhance utilisation of sexual and reproductive health services among migrant adolescents in Ghana: an intervention design. PMID 41116156 · Int J Equity Health · 2025-Oct-20 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transfusion thresholds and other strategies for guiding red blood cell transfusion. PMID 41114449 · Cochrane Database Syst Rev · 2025-Oct-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion. PMID 41107611 · J Neurol · 2025-Oct-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Community-Engaged Approach to Increase Physical Activity Among Black Individuals With Colorectal Cancer: Protocol for a Feasibility Randomized Controlled Trial of the Physical Activity Centers Empowerment Study. PMID 41105939 · JMIR Res Protoc · 2025-Oct-17 This is a protocol for a feasibility randomized controlled trial of a behavioral (physical activity) intervention. It does not present efficacy results, lacks a time-to-event primary endpoint, and has no drug intervention. It is not a Phase III/IIIb or Phase II/III report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
The discovery of Bevacizumab. An historical reappraisal. PMID 41105169 · Clin Exp Med · 2025-Oct-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage). PMID 40985295 · Br J Dermatol · 2025-Oct-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of personlized exercise prescription on muscle mass, physical function, and quality of life in postoperative pancreatic cancer patients undergoing da Vinci robotic surgery: a randomized controlled trial protocol. PMID 41102825 · Trials · 2025-Oct-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Remote ischemic conditioning for the prevention of stroke-associated pneumonia (RICA-2): protocol for a multicenter, prospective, randomized, double-blind, sham-controlled phase III trial. PMID 41102804 · Trials · 2025-Oct-16 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness, cost-effectiveness, and return on investment of the web-based MiLES intervention targeted at employers, to enhance successful return to work of employees with cancer: design of a randomized controlled trial. PMID 41102780 · Trials · 2025-Oct-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality. PMID 41092331 · N Engl J Med · 2025-Oct-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus. PMID 41092329 · N Engl J Med · 2025-Oct-16 This is a Phase 3 randomized trial of a drug (telitacicept) in humans with primary results, but it is for systemic lupus erythematosus (SLE), which is not an oncology indication. Furthermore, the primary endpoint is a composite clinical response (SRI-4) at a fixed time point, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the oncology or time-to-event criteria for inclusion.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer. PMID 41092328 · N Engl J Med · 2025-Oct-16 The report is a randomized trial in oncology with a primary time-to-event endpoint, but it compares surgical procedures (sentinel-lymph-node biopsy vs. lymphadenectomy) and does not involve a drug-containing intervention. The trial phase is not explicitly stated as Phase III/IIIb or II/III in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups. PMID 40102962 · J Clin Endocrinol Metab · 2025-Oct-16 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Vitamin D Supplementation and Testosterone Levels in Breast Cancer Survivors. PMID 41155322 · Int J Mol Sci · 2025-Oct-15 The study is an oncology RCT with a drug intervention and human subjects, but it does not meet the core requirement of a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or any analysis involving Kaplan-Meier or HR). The endpoint is a continuous biomarker (testosterone levels), which is a safety or secondary endpoint, not a time-to-event outcome. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. PMID 41155315 · Int J Mol Sci · 2025-Oct-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Risk-stratified breast cancer screening - a protocol for a non-blinded randomised trial. PMID 41133331 · Dan Med J · 2025-Oct-15 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of goal-directed fluid therapy on the postoperative outcome in head and neck cancer surgery: study protocol for a randomized controlled trial. PMID 41094585 · Trials · 2025-Oct-15 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial. PMID 41094532 · Trials · 2025-Oct-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomised controlled trial (PALACE-3). PMID 41093345 · BMJ Open · 2025-Oct-15 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical outcomes, cost-effectiveness and implementation of individualised physiotherapy using the Specific Treatment Of Problems of the Spine (STOPS) approach for chronic low back pain in Nigeria: a protocol for a prospective sequential clinical trial. PMID 41093330 · BMJ Open · 2025-Oct-15 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis. PMID 41163262 · Dermatitis · 2025-Oct-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -